inClinico
Generative AI-powered platform for data-driven, multimodal prediction of clinical trial outcomes.
Executive Summary
inClinico is a generative AI-powered software platform developed by Insilico Medicine, designed to provide a data-driven, multimodal forecast for predicting the probability of success (PoS) of single clinical trials. It specializes in forecasting outcomes for Phase II clinical trials, leveraging extensive datasets and accumulated expertise in drug discovery and development. As an integral part of Insilico Medicine's broader Pharma.AI platform, inClinico aims to transform pharmaceutical research and development by enhancing decision-making in clinical development. By offering predictive insights into trial outcomes, the platform helps pharmaceutical companies improve the efficiency, quality, and productivity of their R&D efforts, ultimately reducing risks associated with drug candidate progression.
Use Cases
- Predicting the probability of success for Phase II clinical trials.
- Forecasting outcomes for single clinical trials.
- Informing strategic decision-making in clinical development.
- Improving efficiency and reducing risk in pharmaceutical R&D.
Features
Visibility
- Clinical Trial Outcome Visualization: Visualizes the predicted probability of success (PoS) for clinical trials.
Intelligence
- Multimodal Forecast: Provides data-driven, multimodal forecasts for single clinical trial outcomes.
- Phase II Trial Prediction: Specialized system for predicting outcomes of Phase II clinical trials.
- Probability of Success (PoS) Calculation: Calculates the probability of success for clinical trials.
Technical Specifications
- Architecture
- Built on a generative AI framework, inClinico is integrated into Insilico Medicine's broader Pharma.AI platform and leverages the Insilico Secure Application Platform (ISAP) for secure operations.
- Deployment
- SaaS
AI/ML Stack
- Generative AI
- Machine Learning
Integrations
- PandaOmics
- Chemistry42
- Insilico Secure Application Platform (ISAP)
Pricing
- Model
- Contact sales
- Starting Price
- Contact sales
- Target Customer
- Enterprise
- Free Trial
- No
About Insilico Medicine
Insilico Medicine is a clinical-stage biotechnology company that leverages artificial intelligence and deep learning to accelerate drug discovery and development. The company focuses on therapeutic solutions for cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions, utilizing its proprietary Pharma.AI platform to discover novel targets, design new molecules, and advance candidates into human clinical trials.
Alternatives to inClinico
- Insitro Platform by Insitro — Machine Learning to Unravel Biology and Redefine Disease for Better Drugs, Faster.
- iPSC-based disease modeling by Evotec — Leveraging iPSCs for advanced disease modeling in drug discovery.
- Isomorphic Labs Platform by Isomorphic Labs — Harnessing AI to unlock deeper scientific insights for life-changing medicines.
- Just - Evotec Biologics by Evotec — Accelerating biologics development and manufacturing with J.POD® continuous technology.
- Maestro by Schrödinger — Streamlined portal for predictive computational modeling and machine learning in molecular discovery and materials design.
- Molecular Patient Databases (MPD) by Evotec — Integrates deep human health data to accelerate drug discovery and development.
- Nach01 Foundation Model by Insilico Medicine — AI foundation model for AI-native drug discovery, integrated with Microsoft Discovery and available via AWS Marketplace.
- NeuralPLexer by Iambic Therapeutics — Generative AI for accurate protein-ligand complex structure prediction and small molecule drug design.